Alnylam Pharmaceuticals Aktie
268,80
EUR
-1,40
EUR
-0,52
%
320,10
USD
-2,64
USD
-0,82
%
Werbung
Alnylam Pharmaceuticals Aktie Analyse
| 30.03.17 | Alnylam Pharmaceuticals Neutral | UBS AG | |
| 24.11.09 | Alnylam Pharmaceuticals hold | ROTH Capital Partners, LLC | |
| 26.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
| 25.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
| 15.09.08 | Alnylam Pharmaceuticals market weight | Thomas Weisel Partners LLC | |
| 21.08.08 | Alnylam Pharmaceuticals | Focus Money | |
| 10.10.07 | Alnylam Pharmaceuticals market perform | Piper Jaffray & Co. | |
| 14.08.07 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
|
Werbung
|
|||
Werbung
Werbung